Format
Sort by

Send to

Choose Destination

Search results

Items: 1 to 20 of 42

1.

From big data to smart data in Alzheimer's disease. The brain health modeling initiative to foster actionable knowledge.

Geerts H, Dacks PA, Devanarayan V, Haas M, Khachaturian Z, Gordon MF, Maudsley S, Romero K, Stephenson D; Brain Health Modeling Initiative (BHMI).

Alzheimers Dement. 2016 May 26. pii: S1552-5260(16)30246-1. doi: 10.1016/j.jalz.2016.04.008. [Epub ahead of print] Review.

2.

2015 White Paper on recent issues in bioanalysis: focus on new technologies and biomarkers (Part 3--LBA, biomarkers and immunogenicity).

Amaravadi L, Song A, Myler H, Thway T, Kirshner S, Devanarayan V, Ni YG, Garofolo F, Birnboeck H, Richards S, Gupta S, Luo L, Kingsley C, Salazar-Fontana L, Fraser S, Gorovits B, Allinson J, Barger T, Chilewski S, Fjording MS, Haidar S, Islam R, Jaitner B, Kamerud J, Katori N, Krinos-Fiorotti C, Lanham D, Ma M, McNally J, Morimoto A, Mytych D, Nogueira da Costa A, Papadimitriou A, Pillutla R, Ray S, Safavi A, Savoie N, Schaefer M, Shih J, Smeraglia J, Skelly MF, Spond J, Staack RF, Stouffer B, Tampal N, Torri A, Welink J, Yang TY, Zoghbi J.

Bioanalysis. 2015 Dec;7(24):3107-24. doi: 10.4155/bio.15.226. Epub 2015 Dec 4.

3.

Plasma biomarker signature associated with improved survival in advanced non-small cell lung cancer patients on linifanib.

McKeegan EM, Ansell PJ, Davis G, Chan S, Chandran RK, Gawel SH, Dowell BL, Bhathena A, Chakravartty A, McKee MD, Ricker JL, Carlson DM, Ramalingam SS, Devanarayan V.

Lung Cancer. 2015 Nov;90(2):296-301. doi: 10.1016/j.lungcan.2015.09.011. Epub 2015 Sep 15.

PMID:
26424209
4.

Recommendations for Use and Fit-for-Purpose Validation of Biomarker Multiplex Ligand Binding Assays in Drug Development.

Jani D, Allinson J, Berisha F, Cowan KJ, Devanarayan V, Gleason C, Jeromin A, Keller S, Khan MU, Nowatzke B, Rhyne P, Stephen L.

AAPS J. 2016 Jan;18(1):1-14. doi: 10.1208/s12248-015-9820-y. Epub 2015 Sep 16.

PMID:
26377333
5.

Evaluation of miR-122 as a Serum Biomarker for Hepatotoxicity in Investigative Rat Toxicology Studies.

Sharapova T, Devanarayan V, LeRoy B, Liguori MJ, Blomme E, Buck W, Maher J.

Vet Pathol. 2016 Jan;53(1):211-21. doi: 10.1177/0300985815591076. Epub 2015 Jun 29.

PMID:
26123229
6.

Comparison of RNA-seq and microarray-based models for clinical endpoint prediction.

Zhang W, Yu Y, Hertwig F, Thierry-Mieg J, Zhang W, Thierry-Mieg D, Wang J, Furlanello C, Devanarayan V, Cheng J, Deng Y, Hero B, Hong H, Jia M, Li L, Lin SM, Nikolsky Y, Oberthuer A, Qing T, Su Z, Volland R, Wang C, Wang MD, Ai J, Albanese D, Asgharzadeh S, Avigad S, Bao W, Bessarabova M, Brilliant MH, Brors B, Chierici M, Chu TM, Zhang J, Grundy RG, He MM, Hebbring S, Kaufman HL, Lababidi S, Lancashire LJ, Li Y, Lu XX, Luo H, Ma X, Ning B, Noguera R, Peifer M, Phan JH, Roels F, Rosswog C, Shao S, Shen J, Theissen J, Tonini GP, Vandesompele J, Wu PY, Xiao W, Xu J, Xu W, Xuan J, Yang Y, Ye Z, Dong Z, Zhang KK, Yin Y, Zhao C, Zheng Y, Wolfinger RD, Shi T, Malkas LH, Berthold F, Wang J, Tong W, Shi L, Peng Z, Fischer M.

Genome Biol. 2015 Jun 25;16:133. doi: 10.1186/s13059-015-0694-1.

7.

Workshop Report: AAPS Workshop on Method Development, Validation, and Troubleshooting of Ligand-Binding Assays in the Regulated Environment.

Kelley M, Stevenson L, Golob M, Devanarayan V, Pedras-Vasconcelos J, Staack RF, Jenkins R, Booth B, Wakshull E, Bowsher R, Rock M, Dudal S, DeSilva B.

AAPS J. 2015 Jul;17(4):1019-24. doi: 10.1208/s12248-015-9767-z. Epub 2015 Apr 30.

8.

The quintessence of immunogenicity reporting for biotherapeutics.

Shankar G, Arkin S, Devanarayan V, Kromminga A, Quarmby V, Richards S, Subramanyam M, Swanson S.

Nat Biotechnol. 2015 Apr;33(4):334-6. doi: 10.1038/nbt.3181. No abstract available.

PMID:
25850051
9.

Recommendations for adaptation and validation of commercial kits for biomarker quantification in drug development.

Khan MU, Bowsher RR, Cameron M, Devanarayan V, Keller S, King L, Lee J, Morimoto A, Rhyne P, Stephen L, Wu Y, Wyant T, Lachno DR.

Bioanalysis. 2015;7(2):229-42. doi: 10.4155/bio.14.274.

10.

Randomized phase II study of carboplatin and paclitaxel with either linifanib or placebo for advanced nonsquamous non-small-cell lung cancer.

Ramalingam SS, Shtivelband M, Soo RA, Barrios CH, Makhson A, Segalla JG, Pittman KB, Kolman P, Pereira JR, Srkalovic G, Belani CP, Axelrod R, Owonikoko TK, Qin Q, Qian J, McKeegan EM, Devanarayan V, McKee MD, Ricker JL, Carlson DM, Gorbunova VA.

J Clin Oncol. 2015 Feb 10;33(5):433-41. doi: 10.1200/JCO.2014.55.7173. Epub 2015 Jan 5.

11.

Immunoassay Methods.

Cox KL, Devanarayan V, Kriauciunas A, Manetta J, Montrose C, Sittampalam S.

In: Sittampalam GS, Coussens NP, Nelson H, Arkin M, Auld D, Austin C, Bejcek B, Glicksman M, Inglese J, Iversen PW, Li Z, McGee J, McManus O, Minor L, Napper A, Peltier JM, Riss T, Trask OJ Jr., Weidner J, editors. Assay Guidance Manual [Internet]. Bethesda (MD): Eli Lilly & Company and the National Center for Advancing Translational Sciences; 2004-.
2012 May 1 [updated 2014 Dec 24].

12.

A PRIM approach to predictive-signature development for patient stratification.

Chen G, Zhong H, Belousov A, Devanarayan V.

Stat Med. 2015 Jan 30;34(2):317-42. doi: 10.1002/sim.6343. Epub 2014 Oct 27.

13.

The concordance between RNA-seq and microarray data depends on chemical treatment and transcript abundance.

Wang C, Gong B, Bushel PR, Thierry-Mieg J, Thierry-Mieg D, Xu J, Fang H, Hong H, Shen J, Su Z, Meehan J, Li X, Yang L, Li H, Łabaj PP, Kreil DP, Megherbi D, Gaj S, Caiment F, van Delft J, Kleinjans J, Scherer A, Devanarayan V, Wang J, Yang Y, Qian HR, Lancashire LJ, Bessarabova M, Nikolsky Y, Furlanello C, Chierici M, Albanese D, Jurman G, Riccadonna S, Filosi M, Visintainer R, Zhang KK, Li J, Hsieh JH, Svoboda DL, Fuscoe JC, Deng Y, Shi L, Paules RS, Auerbach SS, Tong W.

Nat Biotechnol. 2014 Sep;32(9):926-32. doi: 10.1038/nbt.3001. Epub 2014 Aug 24.

14.

Assessment and reporting of the clinical immunogenicity of therapeutic proteins and peptides-harmonized terminology and tactical recommendations.

Shankar G, Arkin S, Cocea L, Devanarayan V, Kirshner S, Kromminga A, Quarmby V, Richards S, Schneider CK, Subramanyam M, Swanson S, Verthelyi D, Yim S; American Association of Pharmaceutical Scientists.

AAPS J. 2014 Jul;16(4):658-73. doi: 10.1208/s12248-014-9599-2. Epub 2014 Apr 24.

15.

Evaluation of plasma proteomic data for Alzheimer disease state classification and for the prediction of progression from mild cognitive impairment to Alzheimer disease.

Llano DA, Devanarayan V, Simon AJ; Alzheimer’s Disease Neuroimaging Initiative (ADNI).

Alzheimer Dis Assoc Disord. 2013 Jul-Sep;27(3):233-43. doi: 10.1097/WAD.0b013e31826d597a.

PMID:
23023094
16.

Assay Operations for SAR Support.

Beck B, Chen YF, Dere W, Devanarayan V, Eastwood BJ, Farmen MW, Iturria SJ, Iversen PW, Kahl SD, Moore RA, Sawyer BD, Weidner J.

In: Sittampalam GS, Coussens NP, Nelson H, Arkin M, Auld D, Austin C, Bejcek B, Glicksman M, Inglese J, Iversen PW, Li Z, McGee J, McManus O, Minor L, Napper A, Peltier JM, Riss T, Trask OJ Jr., Weidner J, editors. Assay Guidance Manual [Internet]. Bethesda (MD): Eli Lilly & Company and the National Center for Advancing Translational Sciences; 2004-.
2012 May 01 [updated 2012 Oct 01].

17.

HTS Assay Validation.

Iversen PW, Beck B, Chen YF, Dere W, Devanarayan V, Eastwood BJ, Farmen MW, Iturria SJ, Montrose C, Moore RA, Weidner JR, Sittampalam GS.

In: Sittampalam GS, Coussens NP, Nelson H, Arkin M, Auld D, Austin C, Bejcek B, Glicksman M, Inglese J, Iversen PW, Li Z, McGee J, McManus O, Minor L, Napper A, Peltier JM, Riss T, Trask OJ Jr., Weidner J, editors. Assay Guidance Manual [Internet]. Bethesda (MD): Eli Lilly & Company and the National Center for Advancing Translational Sciences; 2004-.
2012 May 1 [updated 2012 Oct 1].

18.

Minimum significant ratio of selectivity ratios (MSRSR) and confidence in ratio of selectivity ratios (CRSR): quantitative measures for selectivity ratios obtained by screening assays.

Goedken ER, Devanarayan V, Harris CM, Dowding LA, Jakway JP, Voss JW, Wishart N, Jordan DC, Talanian RV.

J Biomol Screen. 2012 Aug;17(7):857-67. doi: 10.1177/1087057112447108. Epub 2012 May 14.

PMID:
22584786
19.

A hidden Markov model-based algorithm for identifying tumour subtype using array CGH data.

Zhang K, Yang Y, Devanarayan V, Xie L, Deng Y, Donald S.

BMC Genomics. 2011 Dec 23;12 Suppl 5:S10. doi: 10.1186/1471-2164-12-S5-S10. Epub 2011 Dec 23.

20.

Screening for new biomarkers for subcortical vascular dementia and Alzheimer's disease.

Ohrfelt A, Andreasson U, Simon A, Zetterberg H, Edman A, Potter W, Holder D, Devanarayan V, Seeburger J, Smith AD, Blennow K, Wallin A.

Dement Geriatr Cogn Dis Extra. 2011 Jan;1(1):31-42. doi: 10.1159/000323417. Epub 2011 Jan 14.

Items per page

Supplemental Content

Loading ...
Write to the Help Desk